ASH 2018 | A personalized prediction model to risk stratify patients with MDS
Aziz Nazha
Myelodysplastic syndrome (MDS) patients have very heterogeneous outcomes in terms of overall survival. Here, Aziz Nazha, MD, of the Cleveland Clinic, Cleveland, OH, discusses a personalized prediction model that uses clinical-, molecular-, and transplant-related data predict the probability of survival for individual MDS patients, aiding HCPs and patients in their decision-making prior to transplant. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Related videos
2:54
Pre/post allo-SCT checkpoint inhibitors: a double-edged sword
Naval Daver
4:55
Checkpoint inhibitor combination approaches for AML/MDS: an update
Naval Daver
3:26
Clonal hematopoiesis of indeterminate potential (CHIP): genes, disease predisposition & potential
Siddhartha Jaiswal
1:48
Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS
Saar Gill
1:39
MDS news from ASH 2018
Alan List
